The lymphoma survival rate is better now than it was in the past – especially among patients who are diagnosed before the cancer starts to spread. For instance, according to the National Cancer Institute, nearly 93 percent of patients with regionally contained Hodgkin lymphoma survive at least five years after their diagnosis. This is due in part to a better understanding of the cancer itself, as well as new and better treatments that are continually being discovered by innovators on the leading edge of cancer research, such as Moffitt Cancer Center.
While lymphoma survival rate statistics show what percentage of people with the cancer survive for a specific period of time after diagnosis, it’s important to remember that this data doesn’t take into account a number of individualized prognostic factors, such as:
- Each patient’s lymphocyte counts, lactate dehydrogenase (LDH) levels and red blood cell counts
- Each patient’s specific lymphoma type (there are more than 60 types of non-Hodgkin lymphoma and six types of Hodgkin lymphoma; survival statistics are rarely broken down for each of these unique sub-types)
- Each patient’s age and overall health
- Each patient’s unique response to treatment (and the specific types of treatment and clinical trials that are available at the time of the patient’s diagnosis)
At Moffitt, we know that there is much more to a survival rate than general statistics. Our expert oncologists provide individualized treatment plans for each patient, taking into account the unique makeup of their cancers and specific health needs. Our lymphoma patients have access to a multispecialty team of radiation oncologists, medical oncologists, surgeons and supportive care providers who collaboratively devise a comprehensive treatment plan, which is then reviewed and updated on a weekly basis. This unique approach to treatment is just one of the ways we are working to improve the lymphoma survival rate, as well as each patient’s personal quality of life.
"We are adopting new approaches to lymphoma therapy that uses immunotherapy, targeted therapy and cellular therapy and steering away from the older toxic chemotherapy options."- Hayder Saeed, MD
For more information about the general lymphoma survival rate and how it applies to your unique situation, call 1-888-663-3488 or complete a new patient registration form online. No referrals are necessary to visit Moffitt.